NYSE:GKOS Glaukos (GKOS) Stock Forecast, Price & News $78.37 +2.91 (+3.86%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$75.96▼$78.8450-Day Range$71.77▼$77.8052-Week Range$40.45▼$80.28Volume644,064 shsAverage Volume437,058 shsMarket Capitalization$3.81 billionP/E RatioN/ADividend YieldN/APrice Target$79.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Glaukos MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside0.8% Upside$79.00 Price TargetShort InterestBearish13.57% of Shares Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment1.15Based on 2 Articles This WeekInsider TradingSelling Shares$11.63 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.26) to ($2.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsMedical Sector772nd out of 976 stocksSurgical & Medical Instruments Industry79th out of 100 stocks 2.3 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.00, Glaukos has a forecasted upside of 0.8% from its current price of $78.37.Amount of Analyst CoverageGlaukos has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.57% of the outstanding shares of Glaukos have been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.Change versus previous monthShort interest in Glaukos has recently increased by 1.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Glaukos is -0.90. Previous Next 3.4 News and Social Media Coverage News SentimentGlaukos has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Glaukos this week, compared to 3 articles on an average week.Search Interest6 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows5 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,626,132.00 in company stock.Percentage Held by InsidersOnly 7.80% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.26) to ($2.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -29.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -29.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Glaukos (NYSE:GKOS) StockGlaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.Read More GKOS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GKOS Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comGlaukos (NYSE:GKOS) Stock Rating Reaffirmed by Stifel NicolausSeptember 6, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Glaukos (GKOS)September 27, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.August 31, 2023 | seekingalpha.comGlaukos: Continued Growth Rates, Regulatory Tailwinds, And SupportAugust 3, 2023 | msn.comNeedham Reiterates Glaukos (GKOS) Buy RecommendationAugust 3, 2023 | finance.yahoo.comGlaukos Announces Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comCompared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key MetricsAugust 2, 2023 | msn.comGlaukos (GKOS) Price Target Increased by 20.27% to 82.05September 27, 2023 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>August 1, 2023 | msn.comPiper Sandler Maintains Glaukos (GKOS) Overweight RecommendationAugust 1, 2023 | finance.yahoo.comMedical Device Aug 2 Earnings Roster: MCK, FMS & GKOSJuly 31, 2023 | markets.businessinsider.comAnalyst Ratings for GlaukosJuly 20, 2023 | fool.comGlaukos (GKOS) Stock Price, News & Info | The Motley FoolJuly 20, 2023 | msn.comNeedham Maintains Glaukos (GKOS) Buy RecommendationJuly 19, 2023 | markets.businessinsider.comGlaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: AnalystJuly 19, 2023 | finance.yahoo.comGlaukos' (GKOS) New Tie-Up to Address Chronic Eye DiseaseJuly 17, 2023 | msn.comGlaukos enters marketing agreement with Radius XRJuly 17, 2023 | finance.yahoo.comGlaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.July 14, 2023 | finance.yahoo.comThese 2 Soaring Stocks Finished the Week StrongJuly 14, 2023 | msn.comWhere Glaukos Stands With AnalystsJuly 14, 2023 | finance.yahoo.comGlaukos (GKOS) Stock Hits 52-Week High: More Room to Grow?July 13, 2023 | markets.businessinsider.comGlaukos (GKOS) Gets a Buy from BTIGJuly 12, 2023 | finance.yahoo.comGlaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023July 11, 2023 | msn.comCitigroup Maintains Glaukos (GKOS) Buy RecommendationJuly 6, 2023 | msn.comGlaukos (GKOS) Price Target Increased by 14.45% to 68.23June 26, 2023 | msn.comStifel Maintains Glaukos (GKOS) Buy RecommendationJune 26, 2023 | markets.businessinsider.comStifel Maintains Buy Rating for Glaukos: Here's What You Need To KnowSee More Headlines Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address GKOS Company Calendar Last Earnings8/02/2023Today9/27/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:GKOS CUSIPN/A CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees783Year FoundedN/APrice Target and Rating Average Stock Price Forecast$79.00 High Stock Price Forecast$90.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+2.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,190,000.00 Net Margins-42.61% Pretax Margin-42.15% Return on Equity-19.53% Return on Assets-10.29% Debt Debt-to-Equity Ratio0.72 Current Ratio6.28 Quick Ratio5.66 Sales & Book Value Annual Sales$282.86 million Price / Sales13.32 Cash FlowN/A Price / Cash FlowN/A Book Value$11.11 per share Price / Book6.97Miscellaneous Outstanding Shares48,650,000Free Float44,855,000Market Cap$3.77 billion OptionableOptionable Beta1.22 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Thomas William Burns (Age 62)Chairman & CEO Comp: $1.5MMr. Joseph E. Gilliam (Age 47)Pres & COO Comp: $974.59kMr. Alex R. Thurman (Age 53)Sr. VP & CFO Comp: $373.4kMr. Chris M. Calcaterra (Age 63)Exec. VP of Global Commercial Operations Comp: $198.66kDr. Tomas Navratil Ph.D. (Age 46)Chief Devel. Officer Comp: $721.51kDr. Mory Gharib Ph.D.Co-FounderMr. Christopher William LewisVP of Investor Relations & Corp. AffairsMs. Diane W. Biagianti (Age 60)Sr. VP & Gen. Counsel Ms. Diana A. SchererVP of Compliance & Deputy Gen. CounselMs. Michele M. AllegrettoSr. VP of HRMore ExecutivesKey CompetitorsInari MedicalNASDAQ:NARIMerit Medical SystemsNASDAQ:MMSIIntegra LifeSciencesNASDAQ:IARTAxonicsNASDAQ:AXNXICU MedicalNASDAQ:ICUIView All CompetitorsInsiders & InstitutionsBarclays PLCBought 10,840 shares on 9/21/2023Ownership: 0.070%Wolverine Trading LLCBought 3,895 shares on 8/23/2023Ownership: 0.008%California State Teachers Retirement SystemSold 3,312 shares on 8/21/2023Ownership: 0.114%Teachers Retirement System of The State of KentuckySold 7,016 shares on 8/21/2023Ownership: 0.058%Osaic Holdings Inc.Bought 644 shares on 8/21/2023Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions GKOS Stock - Frequently Asked Questions Should I buy or sell Glaukos stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GKOS shares. View GKOS analyst ratings or view top-rated stocks. What is Glaukos' stock price forecast for 2023? 9 equities research analysts have issued 1-year price targets for Glaukos' shares. Their GKOS share price forecasts range from $48.00 to $90.00. On average, they anticipate the company's stock price to reach $79.00 in the next year. This suggests a possible upside of 2.0% from the stock's current price. View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts. How have GKOS shares performed in 2023? Glaukos' stock was trading at $43.68 on January 1st, 2023. Since then, GKOS shares have increased by 77.3% and is now trading at $77.43. View the best growth stocks for 2023 here. Are investors shorting Glaukos? Glaukos saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 6,480,000 shares, an increase of 9.6% from the August 15th total of 5,910,000 shares. Based on an average daily trading volume, of 461,700 shares, the days-to-cover ratio is presently 14.0 days. View Glaukos' Short Interest. When is Glaukos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our GKOS earnings forecast. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) announced its quarterly earnings data on Wednesday, August, 2nd. The medical instruments supplier reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.02. The medical instruments supplier earned $80.40 million during the quarter, compared to the consensus estimate of $74.73 million. Glaukos had a negative net margin of 42.61% and a negative trailing twelve-month return on equity of 19.53%. The business's quarterly revenue was up 10.6% on a year-over-year basis. During the same period last year, the company earned ($0.83) earnings per share. What ETFs hold Glaukos' stock? ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Alger Weatherbie Enduring Growth ETF (AWEG), SPDR S&P Health Care Equipment ETF (XHE), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC), Xtrackers S&P SmallCap 600 ESG ETF (SMLE) and SPDR S&P SmallCap 600 ESG ETF (ESIX). What guidance has Glaukos issued on next quarter's earnings? Glaukos issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $304.00 million-$308.00 million, compared to the consensus revenue estimate of $298.69 million. What is Thomas W. Burns' approval rating as Glaukos' CEO? 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA). When did Glaukos IPO? (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. What is Glaukos' stock symbol? Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS." Who are Glaukos' major shareholders? Glaukos' stock is owned by a number of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (5.42%), Artisan Partners Limited Partnership (3.82%), State Street Corp (3.66%), Braidwell LP (2.15%), Geode Capital Management LLC (1.88%) and Dimensional Fund Advisors LP (1.72%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Joseph E Gilliam, Thomas William Burns and William J Phd Link. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Glaukos' stock price today? One share of GKOS stock can currently be purchased for approximately $77.43. How much money does Glaukos make? Glaukos (NYSE:GKOS) has a market capitalization of $3.77 billion and generates $282.86 million in revenue each year. The medical instruments supplier earns $-99,190,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. How many employees does Glaukos have? The company employs 783 workers across the globe. How can I contact Glaukos? Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984. This page (NYSE:GKOS) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.